Injectable Drugs for Diabetes Part 7.docx

\#\#\# \*\*Slide 51: Amylin Analog (Pramlintide)\*\* 1\. \*\*Which of the following best describes the mechanism of action of pramlintide (Symlin®)?\*\* \- A. It increases insulin secretion from beta cells \- B. It slows gastric emptying and reduces postprandial glucose spikes \- C. It promotes...

\#\#\# \*\*Slide 51: Amylin Analog (Pramlintide)\*\* 1\. \*\*Which of the following best describes the mechanism of action of pramlintide (Symlin®)?\*\* \- A. It increases insulin secretion from beta cells \- B. It slows gastric emptying and reduces postprandial glucose spikes \- C. It promotes glucagon release from alpha cells \- D. It enhances hepatic glucose production \*\*Answer:\*\* B. It slows gastric emptying and reduces postprandial glucose spikes 2\. \*\*Pramlintide is administered via which route?\*\* \- A. Oral \- B. Intravenous (IV) \- C. Subcutaneous (SC) injection \- D. Inhalation \*\*Answer:\*\* C. Subcutaneous (SC) injection 3\. \*\*In addition to reducing postprandial glucose, what other effect does pramlintide have?\*\* \- A. Increases insulin secretion \- B. Reduces caloric intake and may lead to weight loss \- C. Enhances absorption of glucose from the intestines \- D. Increases hepatic glucose production \*\*Answer:\*\* B. Reduces caloric intake and may lead to weight loss \-\-- \#\#\# \*\*Slide 52: Pramlintide (Symlin®) Side Effects\*\* 1\. \*\*What is a common side effect of pramlintide (Symlin®) therapy?\*\* \- A. Severe hypoglycemia \- B. Weight gain \- C. Hyperglycemia \- D. Renal dysfunction \*\*Answer:\*\* A. Severe hypoglycemia 2\. \*\*Due to the risk of hypoglycemia, what modification should be made when starting pramlintide therapy in insulin-treated patients?\*\* \- A. Increase the insulin dose by 50% \- B. Decrease mealtime insulin doses by 50% \- C. Maintain the current insulin dose \- D. Discontinue basal insulin \*\*Answer:\*\* B. Decrease mealtime insulin doses by 50% 3\. \*\*Which of the following strategies should be used to minimize the risk of hypoglycemia when initiating pramlintide therapy?\*\* \- A. Increase the frequency of meals \- B. Adjust meal timing to coincide with insulin peaks \- C. Closely monitor blood glucose levels after meals \- D. Administer pramlintide only before bedtime \*\*Answer:\*\* C. Closely monitor blood glucose levels after meals \-\-- \#\#\# \*\*Slide 53: Pramlintide - Indications and Considerations\*\* 1\. \*\*Pramlintide is indicated for use in which of the following patient populations?\*\* \- A. Patients with type 1 and type 2 diabetes who are already using insulin \- B. Patients with gestational diabetes \- C. Patients with type 2 diabetes not using insulin \- D. Patients with prediabetes \*\*Answer:\*\* A. Patients with type 1 and type 2 diabetes who are already using insulin 2\. \*\*What is the primary therapeutic role of pramlintide in diabetes management?\*\* \- A. To replace insulin therapy \- B. To reduce postprandial glucose excursions and improve glycemic control \- C. To enhance the effect of oral hypoglycemic agents \- D. To prevent diabetic ketoacidosis \*\*Answer:\*\* B. To reduce postprandial glucose excursions and improve glycemic control 3\. \*\*Which of the following is a key consideration when prescribing pramlintide for a patient already on insulin therapy?\*\* \- A. Pramlintide should be started at the same dose as insulin \- B. Pramlintide requires an increase in basal insulin dose \- C. Mealtime insulin should be reduced by 50% to prevent hypoglycemia \- D. Pramlintide should be administered intravenously \*\*Answer:\*\* C. Mealtime insulin should be reduced by 50% to prevent hypoglycemia